MedTrace Logo

Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension

NCT01093807 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1039

Last updated 2011-04-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of various dosage combinations of lercanidipine (10 and 20 mg)and enalapril (10 and 20 mg) in comparison with their respective components and with placebo.

Conditions

  • Essential Hypertension

Interventions

DRUG

Placebo

once daily for 10 weeks

DRUG

Lercanidipine

10 mg once daily for 10 weeks

DRUG

Lercanidipine

20 mg once daily for 10 weeks

DRUG

Enalapril

10 mg once daily for 10 weeks

DRUG

Enalapril

20 mg once daily for 10 weeks

DRUG

Lercanidipine + Enalapril

10/10 mg once daily for 10 weeks

DRUG

Lercanidipine + Enalapril

10/20 mg once daily for 10 weeks

DRUG

Lercanidipine + Enalapril

20/10 mg once daily for 10 weeks

DRUG

Lercanidipine + Enalapril

20/20 mg once daily for 10 weeks

Sponsors & Collaborators

  • RECORDATI GROUP

    lead INDUSTRY

Principal Investigators

  • Giuseppe Mancia, Prof · Clinica Medica Ospedale S. Gerardo Università Milano Bicocca Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-03-31
Completion
2011-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01093807 on ClinicalTrials.gov